Patent · US Active

Recombinant lentiviral vector for stem cell- based gene therapy of sickle cell disorder

US12139720B2 · kind B2 · utility

0Cited by

0References

22Claims

0Family size

Assignees

Institut National de la Sante et de la Recherche Medicale (INSERM) · FR
UNIVERSITE DE PARIS DESCARTES · FR
ASSISTANCE PUBLIQUE—HÔPITAUX DE PARIS (APHP) · FR
IMAGINE—INSTITUT DES MALADIES GENETIQUES NECKER ENFANTS MALADES · FR

Inventors

Annarita MICCIO · Paris, FR
Vasco MENEGHINI · Brétigny-sur-Orge, FR

Key dates

Filing date	Jun 1, 2018
Grant date	Nov 12, 2024
Priority date	—
Expiry date	Oct 25, 2040

Classification

Technology area (CPC C)Chemistry; Metallurgy
CPC primaryC12N2830/48
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

This invention relates to recombinant lentiviral vectors, compositions thereof, the use of the vectors or the compositions thereof, kits of parts comprising said vectors or compositions thereof and a catalytically active Cas9 or Cpf1 protein, methods for modifying the genome of a hematopoietic stem/progenitor cell (HSPC), and the HSPC obtainable by such methods.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.